TABLE 3.
Results of studies that reported dysregulation of miR-1246 or other genes that interact with miR-1246 in clinical samples.
| Tumor type | Samples | Expression of miR-1246 or other genes (tumor vs. normal) | Kaplan-Meier analysis (impact of miR-1246 dysregulation or other genes dysregulation) | Univariate/Multivariate cox regression | Association of expression of miR-1246 or expression of other genes with clinicopathologic characteristics | Method for assessment of miR-1246 expression | References |
|---|---|---|---|---|---|---|---|
| Colorectal cancer (CRC) | 60 pairs of CRC tissues and ANCTs | Up-regulation of m6A | — | — | lymph node invasion, and distant metastasis | SYBR Premix Ex Taq Kit | Peng et al. (2019) |
| Up-regulation of METTL3 | |||||||
| GEO database: GSE17536 | Up-regulation of METTL3 | Lower OS | — | — | |||
| Serum samples from 82 patients and blood samples from 102 healthy controls | Up-regulation of miR-1246 | — | — | — | Mir-X miRNA RT-qPCR TB Green Kit | Guo et al. (2021) | |
| 40 CRC Patients and 40 healthy controls | Up-regulation of exosomal miR-1246 | — | — | — | |||
| 82 fecal samples | Up-regulation of miR-1246 | — | — | Abundance of Fn | |||
| sera of 37 CRC patients and 30 healthy controls | Up-regulation of miR-1246 | — | — | — | miScript syber green PCR kit (Qiagen) | Salah et al. (2020) | |
| 10 pairs of CRC tissues and ANCTs | Up-regulation of miR-1246 | — | — | — | mirVana™ qRT-PCR microRNA detection kit | Wang et al. (2016) | |
| Serum samples from 43 CRC patients | Up-regulation of miR-1246 in chemoresistant patients | — | — | — | TaqMan miRNA Assay | Jin et al. (2019) | |
| 26 CRC patients | Up-regulation of miR-1246 (lower in post-treatment sera) | — | — | — | Taqman miRNA Assay | Handa et al. (2021) | |
| 181 pairs of CRC tissues and ANCTs | Up-regulation of miR-1246 | — | — | CD44v6 status | SYBR Green | Toden et al. (2019) | |
| 150 pairs of CRC tissues and ANCTs | Up-regulation of miR-1246 | worse OS and DFS | miR-1246 was found to be an independent prognostic factor for OS and DFS | stage IV | |||
| Colorectal cancer (CRC) and Colorectal adenomas (CRA) | 6 CRC and 8 CRA patients | Up-regulation of miR-1246 in both cellular compartments and exosomes (higher in CRC-derived organoids than CRA-derived organoids) | — | — | — | TaqManTMAdvanced miRNA assays | Nagai et al. (2021) |
| Colon cancer | 88 primary CRC patients and 11 healthy controls | Up-regulation of miR-1246 | — | — | — | TaqMan microRNA kits | Ogata-Kawata et al. (2014) |
| Serum from 29 of the patients after surgical resection | Down-regulation of miR-1246 | — | — | — | |||
| 13 CRC patients and 8 healthy controls | Up-regulation of miR-1246 | — | — | — | |||
| Lung cancer | serum from 11 lung cancer patients and 5 healthy control | Up-regulation of miR-1246 | — | — | metastasis | SYBR Green | Yang et al. (2019) |
| 105 NSCLC patients, 50 NMRD patients, and 50 healthy controls | Up-regulation of miR-1246 in NSCLC patients than in patients with NMRD and healthy controls | Worse OS and DFS | Serum exosomal miR-1246, TNM stage, and lymph node metastasis were found as independent prognostic factors for OS. | advanced clinical stage and with lymph node metastasis | miScript SYBR-Green PCR Kit | Huang and Qu (2020) | |
| GEO database: GSE137140 and GSE69732 | Up-regulation of miR-1246 | High expression of UBE2C, UCHL1, TRAIP, TNNT1, TNNI3, RAC3 (PTGs of cmiRNA-1246) = poor OS | — | — | — | Huang et al. (2020c) | |
| High expressions of PITX2, NRAS, ENFA4, DNAJA3, TBCE, and TGIF1(PTGs of cmiRNA-1246) = longer OS in LUAD patients | |||||||
| Lung cancer | 86 pairs of NSCLC tissues and ANCTs | Up-regulation of METTL3 (that upregulates miR-1246) | — | — | Lymph node metastasis, tumor size, and TNM stage | TaqMan MicroRNA Assays | Huang et al. (2021) |
| 86 pairs of NSCLC tissues and ANCTs | Up-regulation of m6A and Up-regulation of miR-1246 | — | — | — | |||
| 52 NSCLC patients and 45 healthy controls | Up-regulation of miR-1246 | — | — | — | QIAGEN SYBR green Master Mix | Zheng et al. (2021) | |
| Cervical cancer | 68 cervical cancer patients and 52 healthy controls | Down-regulation of miR-1246 | — | — | Advanced clinical stage, invasive cervical wall N1/2, HPV positivity | Stem-loop primers using SYBR® Premix Ex Taq™ II kit | Yang et al. (2015) |
| 18 pairs of cervical cancer tissues and ANCTs | Down-regulation of miR-1246 | — | — | — | |||
| 26 cervical cancer patients and 16 healthy controls | Up-regulation of miR-1246 | — | — | — | TaqMan miRNA RT-Kit with stem-loop RT-primer | Nagamitsu et al. (2016) | |
| Esophageal cancer | Serum from 55 ESCC patients and 39 healthy controls | Up-regulation of miR-1246 | — | — | — | miScript SYBR®-Green PCR Kit (Qiagen) | Hoshino et al. (2020a) |
| Serum from 101 ESCC patients and 34 healthy controls | Up-regulation of miR-1246 | Worse 5-years OS and DFS | _ | Tumor depth, positive lymph node metastasis, stage, and survival of patients | |||
| 101 ESCC patients and 35 healthy controls | Up-regulation of miR-1246 | — | miR-1246real was found to be an independent factor for N stage and miR-1246real, and miR-1246pred was found to be an independent factor for N stage and miR-1246pred | — | miScript SYBR®-Green PCR Kit (Qiagen | Hoshino et al. (2020b) | |
| Serum from 101 ESCC patients and 46 healthy controls | Up-regulation of miR-1246 | lower 2-years OS | Expression of miR-1246 was the strongest independent risk factor for a poor survival with a hazard ratio of 4.032 | T3–4, lymph node metastasis, distant metastasis, stage III–IV | TaqMan MicroRNA Assays | Takeshita et al. (2013) | |
| 22 pairs of ESCC tissues and ANCTs | No significant differences | — | — | — | |||
| 32 lymph nodes | Higher in proximal lymph nodes than abdominal lymph nodes, thoracic lymph nodes, and cervical lymph nodes | — | — | — | |||
| Serum from 72 ESCC patients and 50 healthy controls | Up-regulation of miR-1246 | worse OS | — | Tumor invasion and positive lymph node metastasis, albeit insignificantly | miScript SYBR® Green PCR kit (Qiagen) | Hoshino et al. (2021) | |
| Urine from 72 ESCC patients and 50 healthy controls | Up-regulation of miR-1246 | — | — | — | — | ||
| Prostate cancer (PCa) | Serum from 6 PCa patients, 3 BPH patients and 3 healthy controls | Up-regulation of miR-1246 in PCa than BPH and healthy controls | — | — | Advancing PCa stage, lymph node metastasis | TaqMan MicroRNA Assays | Bhagirath et al. (2018) |
| Serum form 44 PCa patients, 4 BPH patients and 8 healthy controls | Up-regulation of ex-miR-1246 in PCa than BPH and healthy controls | — | — | Advancing PCa stage, lymph node metastasis | |||
| 36 pairs of PCa tissues and ANCTs | Down-regulation of miR-1246 | — | — | — | |||
| Breast cancer | Circulating exosomal miRNA from 4 trastuzumab-resistant and 4 sensitive patients | Up-regulation of miR-1246 in trastuzumab-resistant HER2-positive breast cancer patients | poorer EFS | Expression of miR-1246 strongly showed poor EFS for early-stage patients, and poor PFS for metastatic patients | — | miScript SYBR Green PCR Kit (Qiagen) | Zhang et al. (2020) |
| Plasma from 16 breast cancer patients and 16 healthy controls | Up-regulation of miR-1246 in plasma exosomes | — | — | — | Stem-loop primer using TaqMan microRNA Reverse Transcription Kit | Hannafon et al. (2016) | |
| Serum from 56 breast cancer patients and 19 healthy controls | Up-regulation of miR-1246 | — | — | — | Taqman assay | Li et al. (2017) | |
| 11 studies with 921 breast cancer patients | Up-regulation of miR-1246 | — | — | — | — | Wang et al. (2018a) | |
| Breast cancer | Serum from 100 breast cancer patients and 40 healthy controls | Up-regulation of miR-1246 | — | — | — | miScript SYBR Green PCR kit (Qiagen GmbH) | Fu et al. (2016) |
| GEO database: (GSE73002) (1,288 BC patients and 2,686 healthy controls) | Up-regulation of miR-1246 | — | — | — | — | Cui et al. (2018) | |
| GEO database: (GSE73002) (429 BC patients and 895 healthy controls.) | Up-regulation of miR-1246 | — | — | — | |||
| Hepatocellular carcinoma (HCC) | Serum from 33 primary HCC patients, 22 metastatic liver tumor patients, 30 healthy controls | Up-regulation of miR-1246 in metastatic liver tumors | — | — | Females, patients ≤60 years old, and patients with cirrhosis and low level of serum AFP | miScript SYBER Green PCR kit (Qiagen) | Ahmed et al. (2019) |
| 7 HCC patients, 21 cirrhosis patients and 14 healthy controls | Up-regulation of miR-1246 | — | — | — | QX200 EvaGreen ddPCR protocol | Moshiri et al. (2018) | |
| Plasmas from 9 HCC and 6 cirrhotic patients | Up-regulation of miR-1246 | — | — | — | |||
| Plasmas from 22 HCC patients and 11 healthy controls | Up-regulation of miR-1246 | — | — | — | |||
| Plasmas from 24 HCC and 14 cirrhotic patients | Up-regulation of miR-1246 | — | — | — | |||
| Serum from 50 HCC patients and 50 healthy controls | Up-regulation of miR-1246 | shorter OS | — | — | miScript SYBR-Green PCR Kit (Qiagen GmbH) | Chen et al. (2021b) | |
| 50 pairs of HCC tissues and ANCTs | Up-regulation of miR-1246 | — | — | TNM staging, differentiation, and metastasis | |||
| 31 pairs of HCC tissues and ANCTs | Up-regulation of miR-1246 | — | — | — | An Agilent oligonucleotide microarray system (Agilent Gene Spring GX11.51, Agilent Technologies) | Huang et al. (2020a) | |
| Serum from 121 HCC patients, 48 CH patients, 25 LC patients and 15 healthy controls | Up-regulation of miR-1246 in HCC compared to CH, LC, HC | shorter OS and DFS | Serum miR-1246, Albumin, AFP-L3, tumor differentiation, and were independently correlated with poor prognosis | UICC-TNM classification, tumor differentiation, and pathological portal vein invasion | TaqMan Advanced miRNA Assays | Chuma et al. (2019) | |
| 38 liver cancer patients | Up-regulation of miR-1246 | shorter DFS | — | — | miScript SYBR Green PCR kit (Qiagen) | Sun et al. (2014) | |
| 28 pairs of HCC tissues and ANCTs | Expression of miR-1246 was consistent with p53 levels | — | — | — | SYBR PremixEx Taq™ | Zhang et al. (2015) | |
| 62 HCC patients received liver transplantation | Up-regulation of miR-1246 in HCC recipients with HCC recurrence after liver transplantation than those without tumor recurrence | Poor OS and DFS after liver transplantation | Early-phase circulating miR-1246 was found to be significant predictor for predicting OS and DFS of HCC recipients | The serum AST level from day 0 to day 3, serum ALT level from day 0 to day 6 after liver transplantation, and expression of TNF-a | TaqMan MicroRNA Assays | Ng et al. (2016) | |
| 114 pairs of HCC tissues and ANCTs | Up-regulation of miR-1246 | Worse OS and DFS | miR-1246 was an independent prognostic factor for both OS and DFS. | Serum alpha fetoprotein (AFP) level | — | Chai et al. (2016) | |
| 5 LC and 5 HCC patients | Higher in HCC than in LC | — | — | — | TaqMan microRNA Reverse Transcription Kit | Wang et al. (2018b) | |
| 10 CH, 13 LC, 18 HCC patients and 14 healthy controls | Higher in HCC than in LC and CH groups, not different from NC group | — | — | — | |||
| 40 CH, 40 LC, 50 HCC patients and 50 healthy controls | Up-regulation of miR-1246 in HCC than in LC and NC groups | — | — | — | |||
| Oral squamous cell carcinoma (OSCC) | 30 pairs of OSCC tissues and ANCTs | Up-regulation of miR-1246 | poor OS | — | T category, stage, and lymph node metastasis | TaqMan miRNA assays | Lin et al. (2018) |
| 106 pairs of OSCC tissues and ANCTs | Up-regulation of miR-1246 | poor OS | miR-1246 expression, tumor grade and TNM stage were independent prognostic factors for OSCC. | TNM stage, nodal status, and tumor grade | SYBR PrimeScript miRNA RT-PCR kit | Liao et al. (2015) | |
| Plasma from 10 advanced OSCC patients and 10 healthy controls | Up-regulation of miR-1246 | — | — | — | miScript SYBR Green PCR kit (QIAGEN) | Nakashima et al. (2019) | |
| 55 advanced OSCC patients | Up-regulation of miR-1246 | — | — | Tumor stage | |||
| Laryngeal squamous cell carcinoma (LSCC) | Plasma from 61 LSCC patients, 26 healthy controls | Up-regulation of miR-1246 | poor OS | — | — | miScript SYBR Green PCR Kit (QIAGEN) | Huang et al. (2020b) |
| 61 pairs of LSCC tissues and ANCTs | Up-regulation of miR-1246 | poor OS | — | — | |||
| GEO database: (GSE124678, GSE70289, GSE62819) (14 LSCC tissues and 49 ANCTs) | Up-regulation of miR-1246 | — | — | — | — | Jing et al. (2020) | |
| Pancreatobiliary tract cancer | 12 pancreatobiliary tract cancer patients and 13 healthy controls | Up-regulation of miR-1246 | — | — | — | TaqMan MicroRNA Assays | Machida et al. (2016) |
| Melanoma | 43 pairs of melanoma tissues and ANCTs | Up-regulation of miR-1246 | — | — | — | SYBR-Green Premix Ex Taq II | Yu et al. (2020) |
| 42 melanoma patients and 20 healthy controls | Up-regulation of miR-1246 in melanoma patients’ EVs | — | — | metastatic tumor EVs | KAPA SYBR Fast qPCR Kit | Torii et al. (2021) | |
| Glioma | 26 glioma patients | Up-regulation of miR-1246 in GBM than LGG patients | — | — | — | SYBR Premix Ex Taq™ Kit | Qian et al. (2020) |
| CGGA, GEO Databases: (GSE25632, GSE104554) (311 glioma patients) | Up-regulation of miR-1246 | Worse prognosis | miR-1246 was an independent risk factor for OS. | Tumor recurrence | — | Ji et al. (2020) | |
| Pancreatic cancer (PC) | Plasma from 15 PC patients and 15 healthy controls | Up-regulation of miR-1246 | — | — | — | qScript miRNA cDNA Synthesis Kit | Xu et al. (2017) |
| 7 PDAC patients, 4 IPMN patients, 4 NET patients | Up-regulation of miR-1246 in patients with IPMN | — | — | — | |||
| GEO datasets (GSE113486, GSE106817, GSE59856) | Up-regulation of miR-1246 | — | — | — | Hairpin-itTM microRNA RT-PCR Quantitation Kit | Wei et al. (2020) | |
| 120 PC patients, 40 benign pancreatic disease controls (DC) and 40 healthy controls | Up-regulation of miR-1246 in PC than DC and HC group | — | miR-1246 was significant and independent risk factors for PC | Tumor size | |||
| Serum from 34 pairs of pre- and post-operation PC patients | Down-regulation of miR-1246 after surgical resection of malignancies | — | — | — | |||
| Ovarian cancer (OC) | 15 OC tissues and 7 normal ovarian surface epithelium tissues | Up-regulation of miR-1246 in OC exosomes | — | — | Paclitaxel-resistant | PerfeCTa microRNA Assay Kit | Kanlikilicer et al. (2018) |
| Serum from 110 HGSOC patients and 52 Healthy controls | Up-regulation of miR-1246 | — | — | — | Rotor-Gene Thermal Cycler (Qiagen | Todeschini et al. (2017) | |
| serum from 58 HGSOC patients and 13 Healthy controls | Up-regulation of miR-1246 | — | — | — | |||
| 59 high-grade OSC patients | Up-regulation of miR-1246 | — | — | — | TaqMan microRNA reverse transcription kit | Cha et al. (2017) | |
| Clear cell renal cell carcinoma (ccRCC) | 48 pairs of ccRCC tissues and ANCTs | Down-regulation of GABPB1-AS1 (that sponges miR-1246) | better OS | — | inversely associated with tumor size, TNM stage, and Furhman stage | Roche PCR system | Gao et al. (2020) |
| Gastric cancer (GC) | urine from and 7 GC patients and 3 healthy controls | Up-regulation of miR-1246 | — | — | — | Illumina NextSeq 500 SE50 (20M) sequencing | Qian et al. (2021b) |
| Gallbladder cancer (GBC) | Serum EVs from 3 patients with GBC, 3 with Benign and 10 healthy controls | Up-regulation of miR-1246 in GBC than Benign and healthy controls | — | Serum EV miR-1246 was significant independent prognostic factor | Advanced-stage GBC | — | Ueta et al. (2021) |
| GEO database: GSE104165, GSE112408 | Up-regulation of miR-1246 in GBC tissues | — | — | — | |||
| Sarcoma | 22 Sarcoma patients, 17 DDLPS patients, and 3 EWS patients | Up-regulation of miR-1246 in DDLPS | — | — | — | miScript®SYBR®Green PCR kit | Kohama et al. (2021) |